GI CELL Enters Agreement with Optieum Biotechnologies
SEONGNAM, South Korea--(BUSINESS WIRE)--#CAR_NK--GI CELL, Inc. announced today that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targe...
Source: pharmiweb.com